(NASDAQ: CLLS) Cellectis Sa's forecast annual revenue growth rate of 22.69% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 58.7%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.75%.
Cellectis Sa's revenue in 2025 is $54,748,000.On average, 1 Wall Street analysts forecast CLLS's revenue for 2029 to be $11,682,099,552, with the lowest CLLS revenue forecast at $11,682,099,552, and the highest CLLS revenue forecast at $11,682,099,552.
In 2030, CLLS is forecast to generate $13,098,987,864 in revenue, with the lowest revenue forecast at $13,098,987,864 and the highest revenue forecast at $13,098,987,864.